NCT00460746View on ClinicalTrials.gov

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
HIV
Interventions
DRUG

TMC125, Darunavir; Ritonavir

TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;

Trial Locations (1)

Unknown

Los Angeles

All Listed Sponsors
collaborator

Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

INDUSTRY

lead

Tibotec, Inc

INDUSTRY

NCT00460746 - Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects. | Biotech Hunter | Biotech Hunter